Apogee Therapeutics, Inc. Common Stock
APGE
$135.08
+0.08%
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing optimized, novel biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company differentiates itself through antibody engineering aimed at improving efficacy and dosing convenience relative to existing therapies. The current investor narrative centers on the announced acquisition by AbbVie for $10.9 billion, which validates Apogee's pipeline and has driven the stock to near its 52-week high, though the deal's earnings accretion is not expected until 2032, creating debate about near-term value.…
APGE
Apogee Therapeutics, Inc. Common Stock
$135.08
Related headlines
Investment Opinion: Should I buy APGE Today?
Based on the analysis, I rate Apogee as a 'Hold' with a neutral stance. The consensus recommendation is 'hold' with an average target price of $134.85, which is essentially in line with the current price of $134.97, implying no upside. The thesis is that the stock is fairly valued at the acquisition price, and the risk-reward is balanced for existing holders but unattractive for new buyers.
Sign up to view all
APGE 12-Month Price Forecast
The AI assessment is neutral with high confidence, as the stock is essentially at the acquisition price, leaving no room for appreciation. The key factors are the deal's high probability of completion, which supports the current price, but the lack of upside and the long wait for earnings accretion make it unattractive for new investors. The stance would upgrade to bullish if the deal price is increased or if the stock drops below $120, offering a discount. It would downgrade to bearish if the deal faces significant regulatory hurdles or if the company announces a delay in closing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Apogee Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $134.85 and implied upside of -0.2% versus the current price.
Average Target
$134.85
0 analysts
Implied Upside
-0.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$133 - $135
Analyst target range
Apogee is covered by 11 analysts, with a consensus recommendation of 'hold' and a mean recommendation score of 2.87 (where 1 is strong buy and 5 is sell). The average target price is $134.85, which is essentially in line with the current price of $134.97, implying a negligible downside of -0.09%. The distribution shows a mix of hold and neutral ratings, with no strong buy or sell, reflecting the deal-driven nature of the stock where upside is capped by the acquisition price.
Bulls vs Bears: APGE Investment Factors
Apogee presents a unique investment case where the bull and bear arguments are sharply defined by the pending AbbVie acquisition. On the bull side, the $10.9 billion deal validates the pipeline, provides a clear exit, and the stock's strong momentum and low beta offer some downside protection. On the bear side, the stock trades essentially at the acquisition price, offering negligible upside, while the lack of revenue and persistent losses make it entirely dependent on deal completion. The most critical tension is the deal's timing and completion risk: if the acquisition closes as expected, the stock is fairly valued with limited upside; if it fails or is delayed, the stock could fall sharply to its pre-announcement levels. Currently, the bull case has stronger evidence given the strategic fit and market confidence, but the risk-reward is skewed against new buyers at this price.
Bullish
- Acquisition by AbbVie at $10.9B: AbbVie's acquisition of Apogee for $10.9 billion validates the pipeline and provides a clear exit for shareholders. The deal is expected to close, with the stock trading at $134.97, near the 52-week high of $134.99, reflecting high market confidence in completion.
- Strong Momentum and Relative Strength: The stock has surged 268.57% over the past year and 64.32% in the last three months, massively outperforming the S&P 500 (which gained 18.56% over one year). This momentum is driven by the acquisition announcement and strong investor sentiment.
- Robust Balance Sheet with Minimal Debt: Apogee has a debt-to-equity ratio of 0.0098 and a current ratio of 26.57, indicating ample liquidity to fund operations until the deal closes. The company's cash position supports ongoing R&D without financial distress.
- Strategic Fit for AbbVie's Immunology Portfolio: The acquisition extends AbbVie's immunology dominance, with Apogee's pipeline targeting atopic dermatitis, asthma, and other I&I indications. This strategic rationale reduces the risk of deal termination, as AbbVie has a strong incentive to complete the acquisition.
Bearish
- Limited Upside from Current Levels: The average analyst target price is $134.85, essentially equal to the current price of $134.97, implying a negligible downside of -0.09%. With the stock at 99.98% of its 52-week range, there is minimal room for appreciation unless the deal price is revised upward.
- No Revenue and Persistent Losses: Apogee has zero revenue and reported a net loss of $74.1 million in Q1 2026, with R&D expenses rising to $60.8 million from $46.4 million a year earlier. The company is entirely dependent on pipeline success and the acquisition, with no top-line growth to support valuation.
- Deal Accretion Not Expected Until 2032: AbbVie has stated that earnings accretion from the Apogee acquisition is not expected until 2032, meaning near-term financial benefits are minimal. This could lead to investor impatience and potential downward pressure on the stock if the deal faces delays.
- Analyst Consensus is Hold: The consensus recommendation is 'hold' with a mean score of 2.87 (where 1 is strong buy and 5 is sell). No analysts have a strong buy or sell rating, reflecting the neutral stance given the capped upside and deal-driven nature.
APGE Technical Analysis
Apogee's stock has exhibited a powerful sustained uptrend over the past year, with a 1-year price change of +268.57%. The current price of $134.97 sits at 99.98% of its 52-week range (low $35.39, high $134.99), indicating the stock is trading essentially at its highs, reflecting strong momentum and investor optimism. This positioning near the peak suggests the market is pricing in near-certain deal completion, leaving limited upside from technical levels alone.
Beta
0.34
0.34x market volatility
Max Drawdown
-24.6%
Largest decline past year
52-Week Range
$35-$135
Price range past year
Annual Return
+271.4%
Cumulative gain past year
| Period | APGE Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | +2.7% |
| 3m | +71.6% | +1.0% |
| 6m | +86.8% | +12.0% |
| 1y | +271.4% | +18.9% |
| ytd | +78.3% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APGE Fundamental Analysis
Apogee is a pre-revenue clinical-stage biotech, reporting zero revenue in the most recent quarter (Q1 2026) and for all historical periods, so the revenue trajectory is non-existent. The company's focus is on advancing its pipeline, with research and development expenses of $60.82 million in Q1 2026, up from $46.39 million in Q1 2025, reflecting increased investment in clinical trials. The lack of revenue means the investment case hinges entirely on pipeline success and the pending acquisition, not on top-line growth.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-235373000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APGE Overvalued?
Given that Apogee has negative net income and no revenue, the price-to-sales ratio is not meaningful (PS ratio of 0), so I selected the price-to-book ratio as the primary valuation metric, which stands at 5.07. This is the most relevant metric for a pre-revenue biotech with significant cash and no earnings. The trailing PE is -17.89 and forward PE is -25.79, both negative, reflecting the lack of profitability; the more negative forward PE suggests the market expects losses to widen, which is typical for a company in late-stage development.
PE
-17.9x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-17.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant for Apogee, given its pre-revenue status and heavy cash burn. The company reported a net loss of $74.1 million in Q1 2026, with R&D expenses increasing to $60.8 million, up from $46.4 million in the prior year. With no revenue, the company relies on its cash reserves, which are substantial (current ratio of 26.57), but the negative free cash flow of -$235 million TTM indicates a burn rate that will eventually require additional funding if the acquisition does not close. The debt-to-equity ratio is minimal at 0.0098, so financial leverage is not a concern, but the lack of earnings and reliance on pipeline success create high operational risk.